Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on X:
“Can we safely skip chemo in HER2+ eBC?
Pooled WSG data show 94% 5y iDFS in pCR patients without systemic chemo.Favorable markers: PD1, ESR1, Cytotoxic Cells
Unfavorable: PLD1, PPARGC1A
Immune and ERBB2 signals may guide future de-escalation.”
More posts featuring ESMOBreast25.